Impact of timing of ERCP on long term outcomes of ERCP for acute cholangitis – A single center retrospective study
Digestive and Liver Disease · 2024-12 · 56 (12) · 2149-2153
DOI: 10.1016/j.dld.2024.08.037 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive and Liver Disease, 2024-12. Verfasst von Nitin Jagtap und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India. Hauptthemen laut MEDLINE: Cholangiopancreatography, Endoscopic Retrograde, Cholangitis, Length of Stay. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION: Acute cholangitis is a critical medical emergency. The association between the timing of ERCP and clinical outcomes of acute cholangitis is still debated. The current study aims to evaluate whether ERCP within 48 h (urgent) is associated with improved long term clinical outcomes. METHODS: This study is a single-center retrospective analysis of a prospectively maintained database. All patients admitted with acute cholangitis as per Tokyo guidelines at AIG Hospitals, Hyderabad between January 2022 to December 2022 were included. We evaluated the association between urgent ERCP and length of hospital stay, need for reintervention and readmissions, and mortality. RESULTS: A total of consecutive 301 patients underwent ERCP for acute cholangitis; of which 217 patients (31.3 % females; mean age 54.02 ± 14.9 years) underwent urgent ERCP. The remaining 84 (32.1 % females; mean age 56.56 ± 13.9 years) underwent routine ERCP. Fifty-eight (26.7 %) and 22 (26.2 %) patients with Grade III underwent urgent and routine ERCP respectively. The median (IQR) hospital stay for urgent ERCP was 8.00 (6.00 - 11.00) days and for routine ERCP was 11.00(8.00 - 15.00; p value 0.0001), with similar hospital stay post ERCP (p 0.26). There was no significant difference in mortality upto one year between patients who underwent urgent (22.1 %;48/217) or routine ERCP (31.0 %;26/84, p 0.135). The cox proportional hazard model showed that mortality is independently associated with older age (HR 1.034;95 %CI: 1.013 - 1.054; p 0.001) and malignancy (HR 8.64;95 %CI:4.728 - 15.790; p 0.0001). There was no significant difference between two groups in terms of need for reinterventions and readmissions. CONCLUSIONS: Urgent ERCP for acute cholangitis is associated comparable overall mortality, need for reinterventions, and readmissions with decreased total length of hospital stay. There is an unmet need to confirm these findings by randomized controlled studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
- Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India. Electronic address: aigindia@yahoo.co.in.
Zitieren
APA
Jagtap, N., Chavan, D., Rughwani, H., Memon, S. F., Lakhtakia, S., Asif, S., Kalapala, R., Ramchandani, M., & Reddy, D. N. (2024). Impact of timing of ERCP on long term outcomes of ERCP for acute cholangitis – A single center retrospective study. Digestive and Liver Disease, 56(12), 2149-2153. https://doi.org/10.1016/j.dld.2024.08.037
Vancouver
Jagtap N, Chavan D, Rughwani H, Memon SF, Lakhtakia S, Asif S, et al. Impact of timing of ERCP on long term outcomes of ERCP for acute cholangitis – A single center retrospective study. Digestive and Liver Disease. 2024;56(12):2149-2153. doi:10.1016/j.dld.2024.08.037
BibTeX
@article{Jagtap2024,
author = {Jagtap, Nitin and Chavan, Digvijay and Rughwani, Hardik and Memon, Sana Fathima and Lakhtakia, Sundeep and Asif, Shujaath and Kalapala, Rakesh and Ramchandani, Mohan and Reddy, D Nageshwar},
title = {Impact of timing of ERCP on long term outcomes of ERCP for acute cholangitis – A single center retrospective study},
journal = {Digestive and Liver Disease},
year = {2024},
volume = {56},
number = {12},
pages = {2149--2153},
doi = {10.1016/j.dld.2024.08.037}
}
EUVIMED